I think the majority here are with you Baldy in the belief that a quiver of owned drugs for similar but different rare conditions will have considerably greater value than a portion of one straight arrow already in flight.
The conundrum is how to value the owning entity at this current stage of development.
I subscribe to the notion that with clarification of imminent FDA P3 endpoints and disclosure of in-vivo (mouse?) results on those additional indications, potential BP buyers will have enough to start the ball rolling. USD35/AUD55 may well be the first serious bid, but IMO USD50/AUD80 is where fair value for both buyer and sell will rest IF the transaction occurs earlyish in 2025. Later means more value as P3 trial/s are running/concluding.
I can wait for the longer, but reckon it's going to come to a head sooner.
NEU Price at posting:
$13.32 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)